Raphael Pharmaceutical (RAPH) Net Cash Flow (QoQ) (2021 - 2025)
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Net Cash Flow (QoQ) (2021 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 347.06% |
| Sep 30, 2025 | 43.33% |
| Jun 30, 2025 | -196.77% |
| Mar 31, 2025 | 247.62% |
| Dec 31, 2024 | 73.75% |
| Sep 30, 2024 | 52.38% |
| Jun 30, 2024 | -394.74% |
| Mar 31, 2024 | 182.61% |
| Dec 31, 2023 | -136.70% |
| Sep 30, 2023 | 157.53% |
| Jun 30, 2023 | 129.20% |
| Mar 31, 2023 | -228.21% |
| Dec 31, 2022 | 587.50% |
| Sep 30, 2022 | -174.07% |
| Jun 30, 2022 | 175.00% |
| Mar 31, 2022 | -162.07% |
| Dec 31, 2021 | 164.09% |
| Sep 30, 2021 | -187.02% |
| Jun 30, 2021 | 344.71% |
| Mar 31, 2021 | -244.07% |